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 1. Abstract 
Purpose: To assess in a cohort of Caucasian patients exposed to stavudine (d4T) the 
association of polymorphisms in pyrimidine pathway enzymes and HLA-B*4001 
carriage with HIV/Highly active antiretroviral therapy (HAART)-associated 
lipodystrophy syndrome (HALS). 
Methods: Three-hundred and thirty-six patients, 187 with HALS and 149 without HALS, 
and 72 uninfected subjects were recruited. Polymorphisms in the thymidylate synthase 
(TS) and methylene-tetrahydrofolate reductase (MTHFR) genes were determined by 
direct sequencing, HLA-B genotyping by PCR-SSOr Luminex Technology, and 
intracellular levels of stavudine triphosphate (d4T-TP) by a LC-MS/MS assay method. 
Results: HALS was associated with the presence of a low expression TS genotype 
polymorphism (64.7% vs. 42.9%, OR = 2.43; 95%CI: 1.53-3.88, P < 0.0001). MTHFR gene 
polymorphisms and HLA-B*4001 carriage were not associated with HALS or d4T-TP 
intracellular levels. Low and high expression TS polymorphisms had different d4T-TP 
intracellular levels (25.60 vs. 13.60 fmol/10
6
 cells, P < 0.0001). Independent factors 
associated with HALS were (OR [95%CI]: (a) Combined TS and MTHFR genotypes 
(p=0.006, reference category (ref.): ‘A+A’; OR for ‘A+B’ vs. ref.: 1.39 [0.69–2.80]; OR for 
‘B+A’ vs. ref.: 2.16 [1.22–3.83]; OR for ‘B+B’ vs. ref.: 3.13, 95%CI: 1.54–6.35), (b) 
maximum viral load ≥5 log10 (OR: 2.55, 95%CI: 1.56–4.14, P=0.001), (c) use of EFV 
(1.10 [1.00–1.21], P=0.008, per year of use). 
Conclusion: HALS is associated with combined low-expression TS and MTHFR 
associated with high activity polymorphisms but not with HLA-B*4001 carriage in 
Caucasian patients with long-term exposure to d4T. 
 
Keywords:  lipodystrophy, stavudine, thymidylate synthase, methylene-
tetrahydrofolate reductase, HLA-B*4001. 
 
 
 
 
 
2. Introduction 
Despite similarities in antiretroviral drug exposure and similar immunological, 
virological and demographic characteristics, the variability in individual responses to 
antiretrovirals suggests the influence of host-dependent factors such as genetic make-
up. Therefore, several pharmacogenetic studies have analyzed the influence of specific 
polymorphisms on the toxicity of antiretroviral treatment
 
[1]. The analysis of 
pharmacogenetic determinants of toxicity has proved extremely successful with regard 
to the identification of the genetic basis of hypersensitivity reaction to abacavir and its 
causative link to HLA-B*5701 allele [2].  
HIV/ Highly active antiretroviral therapy (HAART)-associated lipodystrophy 
syndrome (HALS) is a long-term adverse effect limiting the doubtless efficacy of 
HAART, although its incidence has decreased since the use of thymidine analogues in 
general, and stavudine (d4T) in particular, has declined in developed countries [3]. The 
impact of HALS on patient quality of life, perceived stigma and psychologically 
devastating consequences may ultimately impact patient adherence to treatment, 
eventually leading to treatment failure [4]. The risk of developing changes in body fat 
distribution is variable despite similar HAART exposure, once again suggesting a 
genetic predisposition [1,5]. Recently, the association of HLA-B*4001 with HALS has 
been reported in a South East Asian population treated with d4T [6]. The association of 
thymidylate synthase (TS) polymorphisms with HALS has been showed in a limited 
sample of patients. We have showed the association of thymidylate synthase (TS) 
polymorphisms with HALS in a limited sample of patients [7,8]. 
We undertook a study to confirm the possible association between HALS, TS 
and methylene-tetrahydrofolate reductase (MTHFR) polymorphisms and HLA-B*4001 
carriage in a well-characterized cohort of Caucasian patients with long-term exposure 
to d4T. Furthermore, in a subset of these patients we determined d4T- triphosphate 
(TP) intracellular levels in peripheral blood mononuclear cells.  
 
 
 
 
3. Methods 
Subjects 
All subjects were recruited at the HIV infection clinic of the Hospital de la Santa 
Creu i Sant Pau, which attends a population of 1708 patients on active follow-up. They 
were patients with an established diagnosis of HIV infection on treatment. Patients 
were eligible if they had HALS and had been receiving therapy with d4T as part of their 
antiretroviral regimes. A normal dose of d4T was 40 mg and 30 mg twice daily if the 
patient weighed > 60 kg or < 60 kg, whereas a reduced dose was 30 mg/12 h and 20 
mg/12 h for patients with a weight ≥ 60 or < 60 kg, respectively. Subjects who were 
hospitalized or had a frank cognitive impairment such as delirium or dementia, 
opportunistic infections, neoplasms or fever of undetermined origin on enrolment 
were not eligible. At the time of study entry no patient used any other drug known to 
influence glucose metabolism or fat distribution such as anabolic hormones or 
systemic corticosteroids, uridine, recombinant human growth hormone, or appetite 
stimulants. Controls were patients followed in the same cohort who had not 
developed HALS despite having had d4T exposure that matched to that of patients (± 6 
months). Uninfected controls were healthy subjects without serologic evidence for HIV 
infection who were used for genetic comparisons. Both HIV-infected patients and 
controls were Caucasian subjects from the area of Barcelona, whose ethnicity could be 
traced to grandparents. The diagnosis of AIDS was based on the 1993 revised case 
definition of the Centers for Disease Control and Prevention
 
[9]. Written informed 
consent was obtained from the patients at study entry.  The study was approved by 
the Ethics Committee of the Hospital de la Santa Creu i Sant Pau. 
 
Body composition measurements 
Subjects were weighed on calibrated scales after removing shoes, outdoor 
clothing, and other heavy items. Body mass index (BMI) was calculated by dividing the 
weight in kilograms by the square of the height in meters. Waist circumference was 
measured to the nearest millimeter using anatomical landmarks as defined for the 
Third National Health and Nutrition Evaluation Survey [10]. 
Whole body dual energy X-ray absorptiometry (DEXA) scans (Hologic QDR-
4500A Hologic, Inc, 590 Lincoln St, Waltham, MA 02154, USA) were conducted by a 
single operator on all the patients. The percentage of fat at the arms, legs and central 
abdomen (calculated from the mass of fat versus lean and bone mass) as well as total 
lean body mass in kilograms was recorded.  
 
Definition of HALS and metabolic syndrome 
Lipoatrophy was identified by patient self-reporting and/or clinician 
observation of relevant changes to the face (loss of cheek and/or preauricular fat 
pads), arms, legs, and subcutaneous abdominal tissue, and confirmed clinically by 
qualitative physical examination. Lipohypertrophy was diagnosed by the presence of 
central adiposity which was defined by a waist-hip ratio (WHR) of > 0.90 in men, and > 
0.80 in women) [10], breast enlargement in women or the appearance of cervical fat 
pads or supraclavicular fat accumulation [11]. Both clinical situations occurred in an 
isolated manner or concomitantly and any combination of them was considered to be 
a mixed syndrome.  
Visual aspects of lipodystrophy were assessed with a lipodystrophy severity 
grading scale (LSGS) based on that reported by Lichtenstein et al. [11]. The degree of 
lipoatrophy and diffuse fat accumulation at each region was rated as absent (score of 
0), mild (noticeable on close inspection, score of 1), moderate (readily noticeable by 
patient/physician, score of 2), or severe (readily noticeable to a casual observer, score 
of 3). The overall score was the mean of the sum of the scores given by patient and 
physician both for fat loss or fat accumulation. A clinical diagnosis of lipodystrophy was 
given to a patient with an overall score > 7. This score was chosen because it would be 
the LSGS of a patient with mild fat loss or mild fat accumulation at all the anatomical 
sites assessed (face, arms, buttocks, legs, abdomen, neck, breasts) [12]. Patients with 
severe fat changes in at least one body location were considered as lipodystrophic 
[12]. In addition, facial lipoatrophy was also assessed through the scale of Fontdevila et 
al. [13] which established four degrees of facial lipoatrophy ranging from normal to 
grade three (or severe). 
The metabolic syndrome was defined according to the U.S. National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III Guidelines [14] and modified as 
recommended in the latest American Heart Association/National Heart, Lung, and 
Blood Institute Scientific Statement [15]. 
 Biochemistry laboratory measurements 
All laboratory investigations were performed as previously described
 
[7]. 
 
Measurement of intracellular d4T triphosphate concentrations 
d4T-TP was from Moravek Biochemicals (CA, USA) and Cl-ATP (2-
chloroadenosine 5'-triphosphate) used as internal standard (IS) was from Sigma-
Aldrich (St Quentin-Fallavier, France). In brief, after 2 blood samples (around 7 mL) 
were obtained, PBMCs were prepared by centrifugation with separation gradient 
medium (Ficoll Histopaque 1077, Sigma) and immediately stored at a temperature 
around -80°C pending analysis. The 2 samples were taken 3 hours after dosing (to 
measure Cmax), and the second, 12 hours after dosing (Cthrough). Our analysis, as pre-
specified in the study protocol, was based on Cthrough, and these concentrations are 
used throughout the manuscript. PBMCs were lysed in 1 ml of ice-cold methanol/Tris 
0.05 M/HCl pH = 5; 70/30 (v/v) containing IS and, after methanol evaporation, a 40-mL 
fraction of the remaining solution was injected into the LC-MS/MS system. 
The LC-MS/MS consisted of a LC-20A prominence liquid chromatograph 
(Shimadzu, Champs sur Marne, France) connected to a triple-quadruple mass 
spectrometer TSQ Quantum Discovery (Thermo Fisher Scientific, Les Ulis, France) 
operating in the negative ESI mode for the detection of both d4T-TP and IS [16]. The 
liquid chromatographic method was used according to a previously published method 
[17]. In these conditions, retention times were around 3.95 and 4.05 min. for d4T-TP 
and IS, respectively. Amount of d4T-TP was determined in the calibrated range from 50 
to 3000 femtomoles (fmol) per cell pellet. Finally, the PBMCs of each clinical sample 
were counted using a validated biochemical test as previously described
 
[18] in order 
to provide results in fmol/10
6 
PBMC. 
 
Genotyping analyses 
The genomic DNA was extracted from the peripheral leucocytes by the salting-
out procedure [19]. In the TS gene, the variable number tandem repeat (VNTR) of 28 bp 
polymorphism and the G>C SNP in the first and second repeat were analyzed. A DNA 
fragment was amplified using previously described PCR conditions and primers [7], and 
directly sequenced using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA). This G to C substitution changes a critical residue in the USF E-box 
consensus element, abolishes USF-1 binding, and alters transcriptional activity. TS 
genotypes of the patients were classified according to Kawakami and Watanabe into 
two groups: high expression type (2/3G, 3C/3G and 3G/3G) and low expression type 
(2/2, 2/3C and 3C/3C) [20]. 
The MTHFR gene polymorphisms (677C→T [rs1801133] and 1298 A→C 
[rs1801131) were determined. These two polymorphisms were analyzed using 
Fluidigm’s Biomark system. This technology is designed for the allelic discrimination 5’ 
nuclease assay. The samples and the TaqMan Gene expression assays (Applied 
Biosystems, Foster City, CA, USA) were prepared following manufacturer’s instructions. 
The 48.48 dynamic arrays used were automatically loaded using an IFC Controller 
(Fluidigm Corporation), and real-time reactions were performed and analyzed using 
BioMark Real-Time PCR System and Analysis software (Fluidigm Corporation), 
respectively. As a quality control, normal, heterozygote and homozygote sequenced 
samples were included on every array for each genotype. MTHFR genotypes were 
classified also into two groups: those associated with a decreased enzymatic activity 
(homozygous 677T, homozygous 1298C and compound heterozygous patients), and 
genotypes associated with an increased enzymatic activity (heterozygous and wild-type 
patients) [21]. 
HLA-B genotyping was performed by PCR-SSOr Luminex Technology. HLA-B40+ 
patients were further analyzed by sequencing of exons 2, 3 and 4 of the HLA-B locus. 
 
Statistical analyses 
Data are expressed as median with interquartile range (IQR) or as frequencies 
and percentages or otherwise specified. Continuous variables were assessed with the 
Mann-Whitney non-parametric test. Categorical data such as genotype and allele 
frequencies were compared by use of the Fisher’s exact test. A logistic regression 
analysis was used to examine the association of HALS with TS polymorphisms and 
other parameters; variables associated with a P < 0.1 in the univariate analyses were 
included in the multivariate stepwise analysis. All analyses were performed with the 
SAS version 9.2 software (SAS Institute Inc., Cary, NC). The level of significance was 
established at 0.05 and all reported P values are two-sided. 
 
4. Results 
Population studied 
We studied 336 HIV-infected, Caucasian patients, exposed to d4T-based 
regimes. Demographic, means of acquiring HIV infection and the virological and 
immunological status of patients with and without HALS are shown in table 1. There 
were 255 men (75.9%) and 81 women (24.1%), with a mean age of 46.5 ± 9.1 years 
(median: 44.0 [IQR: 41.0-50.0 years]). One hundred and thirty-five patients (40.2%) 
had had a prior AIDS-defining condition. No patient was diabetic or was using insulin or 
hypoglycemic agents. Seventy-two uninfected controls were also studied for genetic 
markers.  
 
Antiretroviral drug exposure and immuno-virological status 
The immuno-virological status of patients and controls and their cumulated 
exposure to antiretroviral drugs is shown in tables 1 and 2. Both groups were well 
balanced except for prior AIDS (OR = 1.65; 95%CI: 1.03-2.64, P = 0.0359), a CD4 cell 
nadir < 200 cells/mm
3
 (OR = 1.69; 95%CI: 1.07-2.66, P = 0.0244), and a higher baseline 
viral load ≥ 5 log10 (OR = 2.13; 95%CI: 1.33-3.42, P = 0.0012) more frequent among 
HALS patients, as expected. Eighty-two patients of the HALS group (43.8%) and 71 
patients (47.6%) of the non-HALS group were receiving reduced d4T doses (OR = 0.86; 
95%CI: 0.54-1.35, P = 0.5587). Exposure to thymidine analogues, specifically d4T, was 
comparable between groups (table 2). 
 
Diagnosis of HALS and metabolic syndrome  
All 187 cases with HALS presented with lipoatrophy, but in addition 100 (53.5%) 
had a mixed lipoatrophic-lipohypertrophic phenotype. The anthropometric data of 
patients with and without HALS are shown in table 3. One hundred and forty-one 
patients (41.9%) had metabolic syndrome. Metabolic syndrome was associated with 
the presence of HALS (47.1% vs. 35.6%, OR = 1.61; 95%CI: 1.01.2.57, P = 0.0446) and 
with carriage of the HLA-B*4001 genotype (7.8% vs. 2.1%, OR = 4.04; 95%CI: 1.16-
17.71, P = 0.0244).  
 
HLA-B*4001 carriage and TS and MTFHR genotypes 
One hundred and eighty-five patients (55.1%) had a low expression TS 
genotype whereas 15 patients were positive for HLA-B*4001 (table 4). Low expression 
TS genotype was more frequent in patients with HALS than in patients without (64.7% 
vs. 42.9%, OR = 2.43; 95%CI: 1.53-3.88, P < 0.0001). There were not statistically 
significant differences between HALS and non-HALS patients with respect to MTHFR 
677C→T (P = 0.9282) or MTHFR 1298A→C genotypes (P = 0.9612) neither there were 
for HLA-B*4001 carriage (P = 0.7983). MTHFR genotypes with increased enzymatic 
activity were not more frequent in cases than in controls (63.1% vs. 66.4%, OR = 0.86, 
95%CI: 0.54-1.39, P = 0.6020). When TS and MTHFR genotypes were combined, TS 
genotypes of low expression plus high enzymatic activity MTHFR genotypes were the 
most frequent in HALS patients (Table 4). However, when comparing low expression TS 
genotypes with respect to MTHFR genotype there were not differences between those 
with increased or decreased enzyme activity (OR = 0.82; 95%CI. 0.41-1.64; P = 0.6782) 
(Table 4 ). 
Nine HALS patients (4.5%) and 4 uninfected controls (5.5%) were found to be 
positive for HLA-B*4001 (OR = 0.86, 95%CI: 0.23-3.95, P = 0.7589). There were 
significant differences between these groups with respect to TS polymorphisms (OR = 
2.29; 95%CI: 1.27-4.14, P = 0.0046), but not with respect to MTHFR 677C→T (P = 
0.0940) or MTHFR 1298A→C (P = 0.1080) polymorphisms (table 4). 
There were not significant differences between non-HALS patients and 
uninfected controls with respect to TS (OR = 0.94; 95%CI: 0.51-1.73, P = 0.9482), 
MTHFR 677C→T (P = 0.0940) or MTHFR 1298A→C (P = 0.1080) polymorphisms (P = 
0.1180 and P = 0.0950) or with respect to HLA-B*4001 carriage (P = 0.7315). 
 
d4T-TP intracellular levels and genotypes 
d4T-TP intracellular concentrations were determined in 41 HALS and 45 non-
HALS patients, including those positive for HLA-B*4001. The demographic, 
anthropometric, fat distribution and antiretroviral drug exposure of these patients 
were not significantly different from those of the whole study groups. The median d4T-
TP concentration in the whole cohort was 18.30 fmol/10
6
 cells (interquartile range 
[IQR]: 11.00-28.50 fmol/10
6
 cells). The median concentration of d4T-TP in patients 
treated or not treated with EFV were 19.70 (IQR: 13.80–26.50) and 16.85 (10.30–30.0) 
fmol/10
6
 cells, respectively (P = 0.5659). The median concentrations of d4T-TP for 
patients with or without HALS were 26.70 (IQR: 20.50–54.0) and 13.60 (IQR: 7.60–
18.00) fmol/10
6
 cells (P<0.0001), respectively. Intracellular levels of d4T-TP by 
genotypes and combinations thereof are shown in table 5. 
 
Independent predictors of development of HALS 
When excluding TS genotype, the predictors were (OR [95%CI]: (a) Combined TS and 
MTHFR genotypes (p = 0.006, reference category (ref.): ‘A+A’; OR for ‘A+B’ vs. ref.: 1.39 
[0.69–2.80]; OR for ‘B+A’ vs. ref.: 2.16 [1.22–3.83]; OR for ‘B+B’ vs. ref.: 3.13, 95%CI: 
1.54–6.35), (b) maximum viral load ≥5 log10 (OR: 2.55, 95%CI: 1.56–4.14, P = 0.001), (c) 
use of EFV (1.10 [1.00–1.21], P = 0.008, per year of use) and (d) use of ddI (1.12 [1.03–
1.22], P = 0.053, per year of use); of note, the latter was very close to but did not reach 
statistical significance. 
 
5. Discussion 
Our study does not show an association between the carriage of HLA-B*4001 
and HALS in Caucasian patients, unlike what was found in Thai patients [6], whereas it 
confirms the previous found association of low expression TS polymorphisms, 
especially when combined with MTHFR polymorphisms associated with high enzyme 
activity, with the development of HALS
 
[8]. This is probably related to the fact that low 
expression TS polymorphisms are associated with increased d4T-TP intracellular levels, 
which in turn have also been associated with the development of HALS
 
[8]. However, 
we could not find a correlation between the presence of HLA-B*4001 either with HALS 
or with d4T-TP intracellular levels whereas we could find a contribution of MTHFR 
genotypes to increased d4T-TP intracellular levels. Therefore, our results suggest that 
carriage of HLA-B*4001 is neither a risk for HALS or for high intracellular levels of d4T-
TP in Caucasian patients on a d4T-based antiretroviral regime. 
However, our results may have inherent limitations. This is a cross-sectional 
study and, therefore no causal relationships can or must be drawn. The prevalence of 
percentage of HLA-B*4001 genotype carriage among Thai patients with HALS was 29% 
whereas it was only 4.8% among our patients
 
[6]. However, the frequency of HLA-
B*4001 carriage among our patients is similar to that found in uninfected Caucasian 
Spaniards controls from the same geographic location. Furthermore, the frequency of 
HLA-B*4001 carriage among uninfected controls (5.5%) lies within the range found for 
other Spanish populations and for population from neighboring areas
 
[22].   
TS, a key enzyme in de novo synthesis of pyrimidines, has been shown to 
modulate d4T-TP intracellular levels through a VNTR polymorphism in the TS promoter 
region and a single nucleotide polymorphism (a common G>C change in the second 
repeat of the alleles containing three repeats), both having functional translation
 
[8]. 
We have confirmed that polymorphisms of TS linked to a low expression of the enzyme 
are associated with increased d4T-TP levels which may have consequences in terms of 
toxicity
 
[7,8]. The different genotypes of the VNTR in the TS promoter region occur at 
different frequencies in different populations. In Caucasians, heterozygosity occurs in 
approximately 50% of the population, and each of the two homozygous genotypes is 
found in approximately 25% of the population
 
[23,24]. The same is true for black 
people and for Southwest Asians
 
[23,24]. However, homozygous triple repeat subjects 
were twice as common in Chinese subjects (67%) as in Caucasian subjects (38%)
 
[23]. 
This may explain why HALS, a toxicity that has been directly linked to thymidine 
analogues, which have been widely used all over the world, has been so rarely 
reported in Far East Asian countries
 
[25]. A similar phenomenon, i.e. an ethnic 
distribution of HLA-B*4001 would be a possible explanation of the discrepant findings 
between the Thai study and ours. The HLA-B*40 01 allele frequency is 0.0226 in our 
HIV population, in a sample of 3292 healthy patients from our Hospital and from a 
blood donor center in Madrid was 0.0224 (unpublished data), whereas in Thai 
population the HLA-B*40 01 allele frequency was 0.0550 [22]. The prevalence 
difference between HALS and non-HALS patients found in our study was 0.84%. 
Therefore, our results may rule out differences from −4.19% to +5.49%. If a study is to 
be undertaken in a population similar to ours, then for differences ranging from 1% to 
5% would imply recruiting samples ranging from 381 to 6745 individuals per group 
[26,27]. Recently, an Australian study could not identify any association of HLA-B*4001 
genotype with thymidine analogues-induced peripheral fat loss in Caucasians [28]. In 
this study, carrying HLA A01, B08 and DQ2 supertype alleles protected patients from 
thymidine analogues-associated peripheral fat [28]. 
Another possible explanation could be that HLA-B*4001 is in linkage 
disequilibrium with another close gene, i.e. the tumor necrosis alpha (TNF-α gene) 
[29]. If this was the case, then the inflammatory state would promote the over-
expression of nucleoside transporters [30], leading to increased d4T-TP intracellular 
levels. However, our study does not suggest any link between HLA-B*4001 carriage 
and d4T-TP intracellular levels. A number of studies have assessed the effect of 
different polymorphisms in genes encoding for mitochondrial DNA
 
[1,5], lamin A [1,5], 
TNF-α [1,31] and interleukins 1β and 6 [1,31,32],  in the pathogenesis of HALS. 
However, none of these reports had conclusive results and most of them could not 
have been replicated
 
[32]. In fact, a recent meta-analysis on the role of polymorphisms 
in the TNF-α promoter gene concluded that there is no association with the risk of 
developing HALS
 
[33]. 
MTHFR polymorphisms have also an impact on enzyme activity, which in turn 
may have consequences on TS activity through formation of a ternary inhibitory 
complex with TS, 5,10-methylene tetrahydrofolate and deoxyuridine monophosphate 
[21]. Therefore, they could theoretically contribute both to increased d4T-TP levels and 
HALS. Our results suggest that MTHFR polymorphisms have a marginal contribution 
both to increased d4T-TP levels and HALS. 
The link between EFV exposure and the appearance of HALS has been intensely 
debated in latest years due to controversial evidence [34]. We have found EFV 
exposure to be an independent predictor of HALS in our d4T-exposed population. 
However, EFV implication in HALS pathogenesis has not been proved in studies 
avoiding thymidine analogues [35,36]. We did not find different d4T-TP intracellular 
levels with respect to EFV exposure. Therefore, if EFV is involved, the pathogenic 
mechanism is not through increasing d4T-TP intracellular levels. 
 
 
6. Conclussion 
In summary, our results suggest that HLA-B*4001 carriage is not, whereas TS 
and MTHFR polymorphisms are, associated with HALS in Caucasian HIV-infected 
patients with long-term exposure to d4T-based antiretroviral regimes. 
7. Tables 
 
Table 1. Demographics and viro-immunological status of the population studied 
Parameter HALS (n = 187) No HALS (n = 149) P value 
Age, years 44.0 (40.0-51.7) 44.0 (41.0-49.0) 0.8171 
Men, n (%) 137 (73.3) 118 (79.1) 0.2495 
Means of HIV-1 infection   
MsM, n (%) 53 (28.3) 54 (36.2) 
HTSX, n (%) 77 (41.2) 51 (34.2) 
IDU, n (%) 57 (30.5) 44 (29.5) 
0.2538 
Years since diagnosis 13.0 (9.0-17.0) 13.0 (10.0-15.2) 0.9607 
Smokers, n (%) 89 (47.6) 67 (44.9) 0.6699 
Alcohol abuse, n (%) 12 (6.4) 14 (9.4) 0.4261 
Prior AIDS, n (%) 85 (45.4) 50 (33.5) 0.0344 
HCV co-infection, n(%) 69 (36.9) 58 (38.9) 0.7323 
HBV co-infection, n (%) 23 (12.3) 21 (14.1) 0.7425 
Current CD4 count, cells/mm
3
 551 (387-835) 583 (403-812) 0.4862 
CD4 increase, cells/mm
3
 346 (197-605) 340 (207-518) 0.5254 
Current CD8 count cells/mm
3
 835 (530-1125) 864 (626-1186) 0.4546 
CD8 increase, cells/mm
3
 310 (106-585) 281 (106-602) 0.8508 
Nadir CD4 cell count < 100 cells/mm
3
, n (%) 78 (41.7) 43 (28.8) 0.0164 
Nadir CD4 cell count < 200 cells/mm
3,
 n (%) 112 (59.9) 70 (46.9) 0.0211 
Current viral load, log10, copies/ml 1.28 (1.28-1.28) 1.28 (1.28-1.67) 0.3001 
Undetectable viral load, n (%) 141 (75.4) 108 (72.5) 0.6163 
Maximum viral load ≥ 5 log10, copies/ml 130 (69.5) 77 (51.7) 0.0010 
Viral load decrease, log10, copies/ml -3.72 (-2.94 [-4.35]) -3.68 (-2.60 [-4.26]) 0.4278 
Values are expressed as median and interquartile range, unless indicated. HALS = HIV-1/HAART-associated lipodystrophy 
syndrome, MsM = men who have sex with men, HTSX = heterosexuals, IDU = intravenous drug users, AIDS = acquired 
immune deficiency syndrome, HCV = hepatitis C virus, HBV = hepatitis B virus, ml = millilitres. 
 
 
  
 
Table 2. Antiretroviral drug exposure in the population studied 
 
 
Parameter 
 
HALS (n = 187) No HALS (n = 149) P value 
Current ART composition 
 
 
PI-based, n (%) 82 (43.8) 72 (48.3) 
NNRTI-based, n (%) 98 (52.4) 69 (46.3) 
3 NRTI, n (%) 7 (3.7) 8 (5.4) 
Current d4T use, n (%) 45 (19.2) 30 (14.7) 
0.0660 
Current AZT use, n (%) 17 (9.1) 23 (15.4) 0.0900 
Individual drug exposure 
 
  
       3TC/FTC exposure (m) 56.0 (26.2-95.5) 51.0 (20.0-80.0) 0.0830 
ddI exposure (m) 29.0 (0.0-66.7) 12.0 (0.0-48.0) 0.0139 
EFV exposure (m) 6.0 (0.0-0-51.0) 0.0 (0.0-28.0) 0.0095 
 
All parameters expressed as median and (interquartile range) unless indicated. HALS = HIV-1/HAART-associated 
lipodystrophy syndrome, ART = antiretroviral therapy, PI = protease inhibitor, NNRTI = non-nucleoside reverse 
transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor. *There were not individual drugs exposure 
differences (P<0.1) for stavudine, tenofovir, zidovudine, zalcitabine, abacavir, and nevirapine, m = months, 3TC =
lamivudine, FTC = emtricitabine, ddI = didanosine, EFV = efavirenz. 
 
 
 
 
 
 
 
 
 
 
 Table 3. Anthropometric, metabolic and fat data in d4T-exposed patients 
 HALS (n = 187) No HALS (n = 149) P value 
Weight, kg 66.5 (58.0-73.0) 70.0 (61.5-75.0) 0.2293 
BMI, kg/m
2
 23.4 (21.2-25.5) 23.4 (21.1-25.3) 0.9218 
Waist circumference, cm 87.0 (81.0-94.0) 88.0 (82.0-94.0) 0.8412 
WHR 0.94 (0.90-1.01) 0.93 (0.88-0.97) 0.0109 
LSGS score, units 9.0 (5.0-11.5) 2.0 (0.5-5.0) < 0.0001 
Facial score, units 2.0 (1.0-3.0) 0 (0.0-1.0) < 0.0001 
Systolic BP, mm Hg 120 (110-130) 120 (110-130) 0.0431 
Diastolic BP, mm Hg 75 (70-80) 75 (70-80) 0.7552 
Metabolic syndrome, n (%) 88 (47.1) 53 (35.6) 0.0446 
Total cholesterol, mmol /l 5.05 (4.16-5.93) 4.95 (4.25-5.65) 0.3669 
Triglycerides, mmol /l 1.92 (1.18-3.18) 1.63 (1.09-2.50) 0.0171 
HDL cholesterol, mmol /l 1.09 (0.91-1.35) 1.18 (0.99-1.49) 0.0047 
LDL cholesterol, mmol /l 3.12 (2.49-3.87) 2.77 (2.22-3.38) 0.0007 
VLDL cholesterol, mmol /l 0.89 (0.55-1.31) 0.73 (0.48-1.06) 0.0035 
Fasting glucose, mmol /l 5.4 (4.9-5.9) 5.2 (4.9-5.6) 0.0220 
Fasting insulin, pmol /l 80.0 (55.0-122.2) 61.0 (36.7-86.0) < 0.0001 
HOMA-IR 2.81 (1.85-4.34) 2.00 (1.13-2.99) < 0.0001 
Total body fat, g 12012 (8589-15733) 14089 (10783-19586) 0.0001 
Total body fat, % 18.1 (14.4-23.9) 22.5 (17.1-27.1) 0.0002 
Trunk fat, g 7368 (5573-10550) 7920 (5718-10761) 0.6327 
Appendicular fat, g 3180 (2026-5126) 4275 (2924-6809) < 0.0001 
Trunk/appendicular fat ratio 2.25 (1.68-3.01) 1.64 (1.15-2.37) < 0.0001 
 
All values expressed as median and (interquartile range) unless specified. HALS = HIV-1/HAART-associated lipodystrophy 
syndrome, BMI = body mass index, WHR = waist-hip ratio, LSGS = lipodystrophy grade severity score, BP = blood pressure, 
mmol/l = milimoles per litre, HDL = high density lipoprotein, LDL = low density lipoprotein, VLDL = very low density 
lipoprotein, pmol/l = picomoles per litre, HOMA-r = homeostasis model assessment, g = grams 
 
 
  
Table 4. Gene polymorphisms associated with the presence of HALS in d4T-exposed patients 
 HALS (n = 187) No HALS (n = 149) P value 
TS genotype 
2R/2R, n (%) 46 (24.6) 17 (11.4) 
2R/3C, n (%) 53 (28.3) 33 (22.1) 
2R/3G, n (%) 33 (17.7) 40 (26.9) 
3C/3C, n (%) 22 (11.8) 14 (9.4) 
3C/3G, n (%) 24 (12.8) 36 (24.2) 
3G/3G, n (%) 9 (4.8) 9 (6.0) 
Not 
tested 
Low expression, n (%) 121 (64.7) 64 (42.9) 
High expression, n (%) 66 (35.3) 85 (57.1) 
< 0.0001 
MTHFR 677C→T genotype 
C/C, n (%) 70 (37.4) 56 (37.6) 
C/T, n (%) 85 (45.4) 70 (46.9) 
T/T, n (%) 32 (17.1) 23 (15.4) 
0.9282 
MTHFR 1298A→C genotype 
A/A, n (%) 98 (52.4) 78 (52.3) 
A/C, n (%) 72 (38.5) 56 (37.6) 
C/C, n (%) 17 (9.1) 15 (10.1) 
0.9612 
MTHFR genotypes and enzymatic activity 
Genotypes with increased activity*, n (%) 118 (63.1) 99 (66.4) 
Genotypes with decreased activity  , n (%) 69 (36.9) 50 (33.5) 
0.6020 
Combined TS and MTHFR genotypes 
Low expression and increased activity (B+A), n (%) 78 (41.7) 44 (29.5) 
Low expression and decreased activity (B+B), n (%) 43 (22.9) 20 (13.4) 
High expression and increased activity (A+A), n (%) 40 (21.4) 55 (36.9) 
High expression and decreased activity (A+B), n (%) 26 (13.9) 30 (20.1) 
0.0009 
HLA-B*4001 genotype 
Positive, n (%) 9 (4.8) 6 (4.0) 
Negative, n (%) 176 (93.1) 143 (96.0) 
0.7983 
HALS = HIV/HAART-associated lipodystrophy syndrome, TS = thymidylate synthase, MTHFR = methylene-tetrahydrofolate reductase, * 
Heterozygous and wild-type patients,  
 
Homozygous 677T, homozygous 1298C and compound heterozygous patients 
 
 Table 5. d4T-TP intracellular levels according to TS and MTHFR genotypes, and HLA B4001 carriage. 
 
Genotipe d4T-TP, fmol/10
6
 cells 
 
P value 
Thymidylate synthase 
 
Low expression 25.6 (18.60–33.0) 
 
<0.0001 
 
High expression 13.60 (7.00–20.10) 
 
 
MTHFR genotypes and enzymatic activity 
 
  
Genotypes with increased activity *, n=59  19.40 (11.12–29.17) 0.7236 
Genotypes with decreased activity
±
 n=27  14.80 (11.39–26.90)  
Combined TS and MTHFR genotypes 
 
Low expression and increased activity (B+A), n=29  24.80 (19.27–33.50) <0.0001 
Low expression and decreased activity (B+B), n=12 26.90 (13.90–33.60)  
High expression and increased activity (A+A), n=30 13.50 (6.90–20.10)  
High expression and decreased activity(A+B), n=15  13.6 (10.52–26.50)  
HLA-B*4001 genotype 
 
Positive, n=15 20.20 (12.90–26.85) 
 
0.7847 
Negative, n= 71 16.60 (11.00–29.17)  
 
Values are expressed as median (interquartile range) unless otherwise indicated. TS=thymidylate synthase, 
MTHFR=methylene-tetrahydrofolate reductase,  
*
Heterozygous and wild-type patients,  
±
Homozygous 677T, homozygous 1298C and compound heterozygous patients. 
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